​

Funding Round

Series C - Checkmate Pharmaceuticals

Series C - Checkmate Pharmaceuticals

Investment Firm

Overview

Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.

Announced Date

Dec 12, 2018

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Decheng Capital

Decheng Capital

Decheng Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

3

Investor Name
Participant InvestorDecheng Capital
Participant InvestorvenBio Partners
Participant InvestorF-Prime Capital

Round Details and Background

Checkmate Pharmaceuticals raised $22000000 on 2018-12-12 in Series C

Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 27, 2020
Venture Round - Checkmate Pharmaceuticals
-16.0M
Jun 10, 2020
Series C - Checkmate Pharmaceuticals
11-85.0M
Jun 15, 2017
Series B - Checkmate Pharmaceuticals
5-27.0M
Aug 12, 2015
Series A - Checkmate Pharmaceuticals
2-20.0M

Recent Activity

There is no recent news or activity for this profile.